WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 $
arrow_upward
+0,48%(+0,060) 1 d.
16. okt., 16:00:00 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: WXXWY…
Atvērt
12,29 $
Augsta
12,56 $
Zema
12,20 $
Tirgus kapitalizācija
198,43 mljrd.
Vid. apjoms
61,89 tūkst.
Apjoms
110,85 tūkst.
Augstākā 52 ned.
14,80 $
Zemākā 52 ned.
7,30 $
Beta
0,01
Apgrozībā esošās akcijas
2,06 mljrd.
Darbinieku skaits
15 tūkst.
Atvērt
12,29 $
Augsta
12,56 $
Zema
12,20 $
Tirgus kapitalizācija
198,43 mljrd.
Vid. apjoms
61,89 tūkst.
Apjoms
110,85 tūkst.
Augstākā 52 ned.
14,80 $
Zemākā 52 ned.
7,30 $
Beta
0,01
Apgrozībā esošās akcijas
2,06 mljrd.
Darbinieku skaits
15 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Simply Wall Street
·
pirms 24 minūtēm
What Viasat Doubters Got Wrong
The Fintech Times
·
pirms 1 stundas
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Mitrade
·
pirms 7 minūtēm
Weekly Market Wrap: AI debt fears hit the Nasdaq as Brent pushes back above $100
Yahoo Finance
·
pirms 17 stundām
Michael Burry Warns of a Stock Market ‘Supervolcano’
Profils
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Par “Wuxi Biologics Cayman ADR”
ĢenerāldirektorsZhisheng Chen
Darbinieki14,7 tūkst.
Dibināšanas datums2010
Galvenais birojs-
Sektors-
Tīmekļa vietnewuxibiologics.com